Colazal Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7625884 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(2 years from now)

US7452872 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(2 years from now)

US7452872

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Feb, 2027

(2 years from now)

US7625884

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Feb, 2027

(2 years from now)



Colazal is a drug owned by Valeant Pharmaceuticals International. It is used for treating ulcerative colitis. Colazal uses Balsalazide Disodium as an active ingredient. Colazal was launched by Valeant Pharms Intl in 2000. It is is available in capsule form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 24, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Dec 20, 2013
Pediatric Exclusivity(PED) Jun 20, 2014

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Market Authorisation Date: 18 July, 2000

Treatment: Treatment of ulcerative colitis

Dosage: CAPSULE

How can I launch a generic of COLAZAL before it's drug patent expiration?
More Information on Dosage

COLAZAL family patents

Family Patents